CLEARWATER, FL., United States, via ETELIGIS INC., 11/16/2012 - - Pressure BioSciences compares to Agilent Technologies, Inc. (NYSE:A), Life Technologies Corporation (NASDAQ:LIFE) and Thermo Fisher Scientific, Inc. (NYSE:TMO) as they are all leading providers of important sample preparation or analytical mass spectrometry equipment, which is widely used in the analysis of small molecules including proteins, DNA and RNA.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), an exciting biotech out of Massachusetts, is breaking ground with their barocyclers, microtubes, isolation kits and proprietary Pressure Cycling Technology (PCT) – a platform with more life science applications than any layperson could ever dream of. Currently, the company trades at $0.21 per share with a market cap of $2.24 million. And, anyone who suggests that PBIO is significantly undervalued…is exactly right. Expect PBIO to become a household name (in a laboratory worth its salt that is) within a period of months.
Understandably, infectious microorganisms are fairly difficult to pin down even for most of today’s state-of-the-art molecular-based diagnostic methods. Headaches inevitably arise as scientists strive for a safe sample preparation of potentially harmful substances while simultaneously trying to preserve the sample’s molecular integrity. This is why, with PCT and their Shredder SG3 System, PBIO has virtually no competition. And, now that their product is sufficiently honed and singular, the company aims to shift from development toward sales and marketing. With a recent focus on DNA detection and decontamination, it seems there is no molecule to elusive for PCT, and we expect this miracle product to become increasingly visible over the next year and a half.
In a recent interview with Harry Norman of Proactive Investors, Pressure BioSciences’ CEO Richard Schumacher (formerly the head of three companies with combined market caps of over $1 billion) assured investors of his long-term confidence in the aspiring pressure cycling company and said that the time had come for PBIO to launch an aggressive and comprehensive commercialization plan. Now, let’s take a look at how they are making good on that promise.
On the heels of good news about increased DNA detection in forensic samples, not to mention a 70 percent revenue growth for the second consecutive quarter, PBIO has continued to add top level clients, expand their strategic partnerships and widen an overseas distribution network. On November 7, 2012, Cole-Parmer (a worldwide leader in providing equipment and consumables to labs) announced that they had signed a Supplier Agreement, under which it will distribute the PBI Shredder SG3 System and processing tubes on a non-exclusive basis.
In addition, the company will also be a focus of the keynote address at the opening ceremony of this year’s ClinMicro – a veritable jamboree of biotech bigwigs with a mix of microbiologists, microbial Genomics experts, leading companies and powerful academics from around the world. It was announced on Halloween Day that Dr. Bradford Powell, President of Cernomics Solutions, would present PBIO and PCT in his keynote address and in another main session presentation later in the conference being held at the Hilton San Antonio Airport starting November 12.
Before ClinMicro, Dr. Powell talked up PCT saying, “It has already been demonstrated that the PCT Platform has the ability to inactivate and extract live attenuated virus and bacteria that are used as models of important biological threat agents. To that end, protein and nucleic acid markers from Venezuelan Equine Encephalitis virus and Bacillus anthracis (Sterne) spores were processed in less than an hour, as safely and as effectively as conventional procedures that often require more time, as well as large investments for facilities infrastructure, training, and oversight. Consequently, we are confident that the PCT Platform has the potential to provide an adaptable, cost-effective solution for advancing the capability, safety, and performance of assays used in the clinical and microbial genomics sciences. This is a transformative technology whose time, we believe, has come for broad application and acceptance.”
Dr. Powell is absolutely correct. The possibilities of PCT are almost limitless. The technology could already improve test samples, aid clinical laboratory medicine, and improve healthcare across the globe. Embracing this microbiological advancement means simplifying the job of people who track criminals and catching a potentially harmful virus where we wouldn’t have otherwise looked. It means stopping contaminated low-quality food before something like “pink slime” reaches our children’s school lunch line. And, these endeavors seem more than worthy of federal funding, scientific sponsorship or some such hefty investment. In other words, the FBI already has use for PCT’s capabilities, and so does the FDA, the USDA, and the CDC, so it seems only a matter of time before its use becomes widespread. Either way, we’d keep a watchful eye on this fascinating and promising small cap. Perhaps Dr. Nate Lawrence, Vice President of Sales and Marketing of PBI, summed up PBIO’s current situation best with this recent comment:
“We believe that this increased understanding of infectious microbes and microbial genomics, aided by the use of our novel PCT Platform, will accelerate the development of improved diagnostics, therapeutics, and food safety measures. We also believe that these clear sample-processing advantages will continue to compel researchers to integrate the PCT Platform into their basic scientific studies and clinical applications, resulting in measurable revenue growth and product visibility for Pressure BioSciences, Inc.”
Always read our full disclaimer/disclosure pertaining to this article http://tomorrowsbluechips.com/disclaimer/
922 Mc Mullen Booth Rd
Clearwater FL 33759
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the significant improvement in the detection of DNA in forensic samples with the use of the PCT Platform over other extraction methods; that the PCT Platform could potentially enhance the detection of DNA in forensic samples containing contaminants/inhibitors, specifically bone samples; the Company's plan to speed up the development of its instruments and consumables for commercial forensic use; the conclusions related to the advantages of the PCT Platform reported by the University of North Texas and the Harris Country Institute of Forensic Sciences; that PCT could improve the processing and results of DNA testing and lead to solving crimes that are unsolved today; that the Company will be successful in accelerating the development of its forensic-related instruments and consumables, and that the release of these products will have a positive impact on 2013 revenue; and the size of the life sciences sample preparation market. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's and its strategic partners/distributors sales forces may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods; that other researchers may not be able to replicate the data reported in the studies mentioned; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital beyond December 2012. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the additional capital necessary to fund its operations beyond December 2012 on acceptable terms, if at all. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
SOURCE : Seraphim Strategies Clearwater FL, November 16, 2012